Skip to main content
Premium Trial:

Request an Annual Quote

Todos Medical Obtains $3.4M Investment From Yozma Group Korea

NEW YORK ─ Todos Medical on Monday announced a $3.4 million strategic investment in its business by venture capital firm Yozma Group Korea.

Under the terms of the agreement, Yozma has been issued a one-year, $3.4 million promissory note convertible into common shares at a fixed price of $0.0599 per share, Todos said.

Rehovot, Israel-based Todos said it intends to use the proceeds for general working capital, to retire outstanding convertible notes, and to complete the acquisition of proteomics test developer Provista Diagnostics.

Todos announced more than a year ago that it had entered into an exclusive option agreement to acquire Provista.

Todos is a developer of in vitro diagnostic tests for the detection of cancers and neurodegenerative diseases and has inked agreements to distribute SARS-CoV-2 test kits including PCR- and antibody-based tests. 

South Korea-based Yozma said in a statement that it sees a "significant opportunity" to fuel Todos' growth with an infusion of capital as it adds "complementary products" to an expanding sales pipeline.

Further, Yozma added that it sees an opportunity to help drive cross-border collaboration for Todos in South Korea.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.